Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03089515
Other study ID # 16-01589
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2017
Est. completion date September 1, 2021

Study information

Verified date January 2022
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many "Survivors" in the World Trade Center (WTC) clinical program have a clinical syndrome characterized by chronic obstruction in small airways and persistence of lower respiratory symptoms despite therapy. This study will test the hypothesis that persistent symptoms in WTC "Survivors" are associated with abnormal small airways whose dysfunction is amplified during exercise and is associated with biologic evidence of inflammation and remodeling. The results from this study will have important treatment implications for our WTC population with potential applicability to larger populations with either inhalational lung injury and/or airway diseases such as asthma and chronic obstructive pulmonary disease.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date September 1, 2021
Est. primary completion date September 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: sACOS patients - Previously participated in ULRS study and signed consent to be recontacted, or - Patient in the WTC EHC and signed consent to be recontacted - Onset of lower respiratory symptoms (LRS) after 9/11/01 - ACT < 20 at WTC EHC Monitoring visit - Presence of LRS on Study Visit 1 - ACT<20 at Study Visit 1 - FEV1 > 70% predicted Study Visit 1 - Using ICS/LABA (Advair HFA equivalent > 115/21 mcg bid) or Fluticasone (110 mcg bid or equivalent) for at least 1 month before Study Visit 1 - CXR without parenchymal abnormalities Control - Patient in the WTC EHC and signed consent to be recontacted - of lower respiratory symptoms on WTC EHC Monitoring Visit of WTC EHC - Absence of lower respiratory symptoms on Study Visit 1 - FEV1 > 70% predicted on monitoring - Not on any ICS/LABA/LAMA Exclusion Criteria: sACOS - >10py tobacco use - Unstable cardiac disease - Systolic BP > 180 mmHg or Diastolic BP > 120 mmHg - Oxygen saturation < 90% - Uncontrolled HTN, DM - Musculoskeletal inability to exercise - Use of long acting muscarinic antagonist in the past 2 weeks - Current use of oral corticosteroids - Other pulmonary disease, including sarcoidosis, ILD - Currently pregnant or with plans to become pregnant or lactating - History of narrow angle glaucoma - Known prostate hyperplasia or bladder-neck obstruction Control - >10py tobacco use - Unstable cardiac disease - Systolic BP > 180 mmHg or Diastolic BP > 120 mmHg - Oxygen saturation < 90% - Uncontrolled HTN, DM - Musculoskeletal inability to exercise - Use of ICS/LABA/SABA/LAMA individually or in combined formulation - Current use of oral corticosteroids - Other pulmonary disease, including sarcoidosis, ILD - Currently pregnant or with plans to become pregnant or lactating - History of narrow angle glaucoma - Known prostate hyperplasia or bladder-neck obstruction

Study Design


Intervention

Other:
Cardio-Pulmonary Exercise Testing (CPET)
This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Resting Lung Function using Spirometry following Forced Oscillation Techniques functional impairment at rest and with increased respiratory frequency (spirometry and forced oscillation techniques; FOT). 4 Months
Primary Measure of Lung Function using spirometry after inhalation of a targeted anti-muscarinic agent. Spirometry (meaning the measuring of breath) is the most common of the pulmonary function tests (PFTs), measuring lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. 4 Months
Secondary Comparison of measure of serum marker IL-6 Inflammation is caused by extra protein released from the site of inflammation that circulates in the bloodstream. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscosity (PV) blood tests are commonly used to detect this increase in protein. In this way they are used as markers of inflammation. 4 Months
Secondary Comparison of measure of serum marker IL-8 Inflammation is caused by extra protein released from the site of inflammation that circulates in the bloodstream. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscosity (PV) blood tests are commonly used to detect this increase in protein. In this way they are used as markers of inflammation. 4 Months
Secondary Comparison of measure of serum marker CRP Inflammation is caused by extra protein released from the site of inflammation that circulates in the bloodstream. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscosity (PV) blood tests are commonly used to detect this increase in protein. In this way they are used as markers of inflammation. 4 Months
Secondary Th2 inflammation By measure of fibrinogen Inflammation is caused by extra protein released from the site of inflammation that circulates in the bloodstream. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscosity (PV) blood tests are commonly used to detect this increase in protein. In this way they are used as markers of inflammation. 4 Months
Secondary Th2 inflammation By measure of periostin Inflammation is caused by extra protein released from the site of inflammation that circulates in the bloodstream. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscosity (PV) blood tests are commonly used to detect this increase in protein. In this way they are used as markers of inflammation. 4 Months
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
Recruiting NCT05306743 - PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD. N/A